Kornimate/medical-research-clean huggingface dataset:
profile and antithrombotic management of patients with nvaf attending internal medicine departments in spain (perfilar study)

Conditions: Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke

Summary: this is a national, multicenter, cross-sectional, observational study within a convenience sample of internal medicine departments from 100 hospitals in spain which agree to participate in the study. this study will be a cross-sectional chart review which will require the collection of data from medical records and from face-to-face interviews conducted during the inclusion visit. physician interviews are needed to collect three variables of interest, recommended by the spanish society of internal medicine as necessary data about profile and management of nvaf patients: cognitive deterioration based on the patient's responses, physician's assessment of the patient's life expectancy, and physician's opinion of the antithrombotic treatment previously prescribed. the investigators will only provide their opinion on previously prescribed therapies (i.e. prescribed before f2f). hospitals to be contacted for the study include those known to participate in observational studies in spain; the hospitals will therefore not be a random sample of spanish hospitals.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * adult patients (≥18 years old) * patients diagnosed with non-valvular atrial fibrillation (nvaf) any time prior to the inclusion date (prevalent or incident patients) * patients treated or not treated with an antithrombotic therapy * treated patients should have begun treatment prior to the inclusion visit * patients attending internal medicine departments, either for a hospital appointment (outpatients) or hospitalization (inpatients) for any reason) * patients which signed the informed consent exclusion criteria: * patients diagnosed with valvular atrial fibrillation any time in their medical records * patients with anticoagulant treatment prescribed for venous thromboembolic disease any time prior to the inclusion date * patients which participated in any clinical trial with anticoagulant and/or antiplatelet agents in the previous six months * patients incapable of giving their informed consent
survey of people with diabetes, caregivers of people with diabetes parents of children and young people with diabetes

Conditions: Diabetes

Summary: a survey of people with diabetes and caregivers of people with diabetes and parents of children and young people with diabetes in denmark in order to assess perceived diabetes related health and wellbeing and perceived access to and gaps in medical care, support and other financial and support services.

a questionnaire survey was designed for online completion by people with diabetes and caregivers of people with diabetes and parents of children and young people with diabetes in denmark in order to assess their perceived diabetes related health and wellbeing and perceived access to and gaps in medical care, support and other financial and support services. the aim is for the survey to provide a cross-sectional assessment of present access to health, wellbeing and care for people with diabetes and caregivers in denmark and to establish a survey tool suitable for ongoing long-term monitoring of well-being, care and support to people with diabetes and caregivers in denmark.

Eligibility criteria:
inclusion criteria: * age over 18 exclusion criteria: * not able to complete online questionnaire
nutrition support for hirschsprung disease

Conditions: Nutrition Supporting; Hirschsprung Disease; Infants; Prospective Study

Summary: a multi-center, prospective,randomized, non-blind, controlled study was conducted to investigate the effects of different pre-operative nutritional support modes on perioperative nutritional status, surgical treatment success rate, and rehabilitation process in children with hirschsprung disease.


Eligibility criteria:
inclusion criteria: 1. children aged 0-5 years. 2. clinical diagnosis with hirschsprung's disease who requires surgery; exclusion criteria: 1. complicated with severe complications such as enterocolitis associated with hirschsprung disease; 2. history of diseases associated with various organ systems that may be life-threatening; 3. other severe digestive tract malformations or other diseases that may interfere with the treatment or compliance of the child; 4. patients who have participated in other clinical trials within the last 1 month; 5. any other conditions in which the investigator considers it inappropriate to participate in the trial.
premixed vs basal bolus insulin therapy in older patients with type 2 diabetes

Conditions: Type 2 Diabetes Treated With Insulin

Summary: the purpose of this study is to compare efficacy and security of premixed insulin treatment vs basal bolus insulin treatment in older patients with poorly controlled type 2 diabetes.


Eligibility criteria:
inclusion criteria: * outpatients * age ≥ 65 years old * type 2 diabetes mellitus * hba1c ≥9% (74 mmol/mol) * previously treated with one or two doses of basal insulin and oral hypoglycaemic agents exclusion criteria: * severe insulin-resistance * high doses of corticosteroids * chemotherapy treatment * high comorbidity * bad compliance of the treatment * frequent severe hypoglycaemia

Keywords: premixed insulin therapy basal-bolus insulin therapy type 2 diabetes elderly
pre-visit digital messaging improves patient reported outcome measure participation prior to the orthopedic ambulatory visit

Conditions: Orthopedic Disorder

Summary: patient-reported outcomes measurement information system (promis) forms will be administered remotely to consecutive orthopaedic patients presenting for new physician clinic visits. these patients will be sent either reminder e-mails, reminder digital patient portal ("mychart") messages, or no reminder messages at all concerning promis form completion at timepoints prior to their respective clinic visits and promis form completion rates will consequently be assessed. the primary objective of this study is to develop an understanding of whether pre-visit reminder messages influence promis form completion in orthopaedic patients.


Eligibility criteria:
inclusion criteria: * at least 18 years old * english speaking * no previous prom form completion at the healthcare system * seeing a respective orthopedic provider for the first time * active registration with the electronic medical record (emr; epic, verona, wi) patient portal ("mychart") * valid e-mail address. exclusion criteria: * under 18 years old * non-english speaking * previous prom form completion at the healthcare system * seeing a respective orthopedic provider for follow-up * no active registration with the electronic medical record (emr; epic, verona, wi) patient portal ("mychart") * no valid e-mail address.

Keywords: promis patient reported outcomes measurement information system
effects of dry needling on stiffness in latent trigger points

Conditions: Trigger Points

Summary: the purpose of this study is to determine whether application of dry needling (dn) is effective for reduced on stiffness in latent trigger point (ltrp) of upper trapezius. the secondary purposes are to determine the correlation on two elastography for stiffness measure (shear-wave elastography and strain elastography). randomized controlled trial, in parallel with cross-control design. two groups with ltrp in upper trapezius, and will be randomly selected to dn group or sham-dn group.


Eligibility criteria:
inclusion criteria: * age between 18 and 30 years * the presence of ltrp in the middle third of the upper trapezius muscle on the dominant side * being able to provide written informed consent * being able to follow instructions and realize clinical tests exclusion criteria: * any pharmacological therapeutic * any medical treatment or physical therapies at cervical region during the 6-month before this study - any diagnosed health problem * any history of head and upper extremity surgery or trauma * any red flags to dn, (ie: metabolic diseases, pregnancy, kinesiophobia, infection, cancer) * absence of recurrent history of neck pain * no neck pain symptomatology the previous 6 months * cervical disk herniation

Keywords: pain latent trigger point stiffness dry needling
rehabilitation of people with post-tuberculosis lung disease

Conditions: Pulmonary Tuberculosis

Summary: tuberculosis (tb) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness. post-tb lung disease (pd-ptb) encompasses lung diseases and pathologies that occur after one or more episodes of tb, which can affect the patient's lung health and cause disabling symptoms that strongly affect their long-term health. in 2020, it was estimated that there were 155 million tb survivors still alive worldwide, with a large proportion of them carrying functional sequelae with profound socioeconomic repercussions. thus, the aim of this study is to evaluate the effect of pulmonary rehabilitation (pr) on functionality and health-related quality of life (hrqol) of people with pd-ptb and to build a pd-ptb severity scoring system based on the data. of pre-rp individuals using artificial intelligence technique.

tuberculosis (tb) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness. post-tb lung disease (pd-ptb) encompasses lung diseases and pathologies that occur after one or more episodes of tb, which can affect the patient's lung health and cause disabling symptoms that strongly affect their long-term health. in 2020, it was estimated that there were 155 million tb survivors still alive worldwide, with a large proportion of them carrying functional sequelae with profound socioeconomic repercussions. thus, the aim of this study is to evaluate the effect of pulmonary rehabilitation (pr) on functionality and health-related quality of life (hrqol) of people with pd-ptb and to build a pd-ptb severity scoring system based on the data. of pre-rp individuals using artificial intelligence technique. this is a randomized controlled trial, in which the sample will be divided into two groups: intervention for 12 weeks with pr and standard care. functional capacity will be evaluated pre- and post-pr through the glittre-adl test with incorporation of dynamic ventilation, lung function (including impulse oscillometry), respiratory and peripheral muscle function, general fatigue and hrqol. it is expected that ptb-pd patients will benefit significantly and, therefore, be able to (re)enter society, especially in job market.

Eligibility criteria:
inclusion criteria: * patients with post-tuberculosis lung disease, clinically stable and able to perform \>80% of training sessions. exclusion criteria: * presence of comorbidities not related to pd-ptb. * patients with inability to perform tglittre. * patients who have cognitive changes that impair their inclusion in the study. * treatment abandonment during the application of the pr protocol. * uncontrolled hypertension or use of psychotropic medications. * any significant limitations due to osteoarthropathy. * having had any orthopedic surgery in the previous year.

Keywords: pulmonary tuberculosis tuberculosis sequelae rehabilitation adl-glittre test functionality quality of life
efficacy and safety of acitretin plus pioglitazone in patients with psoriasis

Conditions: Psoriasis

Summary: acitretin, when given in combiantion with pioglitazone might achieve better and/or more rapid control of moderate to severe chronic plaque type psoriasis.


Eligibility criteria:
inclusion criteria: * patients with chronic plaque type psoriasis having body surface area involvement of \> 20% * patients of either sex * females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year * age range 18-65 years exclusion criteria: * females of child bearing potential * h/o hypersensitivity to acitretin * impaired hepatic function (serum bilirubin, ast, alt and alkaline phosphatase \>1.5 times the upper limit of normal) * impaired renal function (serum creatinine \>1.5mg% in males and \>1.4 mg% in females) * hyperlipidemia * bmi \>30 kg /m2 * h/o excessive alcohol use * diabetes mellitus * congestive heart failure * ischemic heart disease
opioid growth factor in treating patients with advanced pancreatic cancer that cannot be removed by surgery

Conditions: Pancreatic Cancer

Summary: rationale: opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor. purpose: this phase ii trial is studying how well opioid growth factor works in treating patients with advanced pancreatic cancer that cannot be removed by surgery.

objectives: primary * determine the growth inhibitory effects of opioid growth factor (\[met\^5\]-enkephalin) in patients with advanced unresectable pancreatic cancer. secondary * determine the pharmacokinetics of this drug in these patients. * determine the quality of life of patients treated with this drug. * determine the pain control, depression, and nutritional status of patients treated with this drug. outline: this is an open-label study. patients receive opioid growth factor (\[met\^5\]-enkephalin) iv over 45 minutes once weekly. treatment continues in the absence of disease progression or unacceptable toxicity. quality of life is assessed at baseline, every 4 weeks during study treatment, and at the completion of study treatment. patients are followed weekly for survival. projected accrual: a total of 50 patients will be accrued for this study.

Eligibility criteria:
inclusion criteria * diagnosis of pancreatic cancer * advanced, unresectable disease * must have failed or refused prior standard chemotherapy (e.g., gemcitabine or fluorouracil) for pancreatic cancer * measurable disease by radiography * age over 18 * performance status karnofsky 50-100% * hematopoietic * absolute neutrophil count ≥ 1,500/mm\^3 * wbc ≥ 3,500/mm\^3 * hemoglobin ≥ 8.5 g/dl * platelet count ≥ 100,000/mm\^3 * bilirubin ≤ 4.0 mg/dl (stents allowed) * pt or inr ≤ 2 seconds over control or ≤ 1.8 (unless on warfarin) renal \& metabolic * bun ≤ 30 mg/dl (hydrated) * creatinine ≤ 2.0 mg/dl * sodium ≥ 130 mmol/l * potassium ≥ 3.2 mmol/l * glucose 60-300 mg/dl * pulse 60-110 beats/minute * systolic blood pressure 90-170 mm hg exclusion criteria * no primary cns tumors or known brain metastases cardiovascular * - congestive heart failure * symptoms of coronary artery disease * cardiac arrhythmia * poorly controlled hypertension * myocardial infarction within the past year * abnormal ekg * asthma * hronic obstructive pulmonary disease * pregnant or nursing * fertile patients must use effective contraception * serious infection requiring antibiotics within the past 2 weeks * poorly controlled diabetes * seizure disorders * fever \> 37.8° c * other malignancy within the past 5 years * concurrent chemotherapy * concurrent oral steroids * concurrent radiotherapy * surgery within 4 weeks

Keywords: recurrent pancreatic cancer stage iii pancreatic cancer stage iv pancreatic cancer
evaluation of near visual acuity with odysight, a smartphone based medical app in comparison to a standardized method

Conditions: Near Vision

Summary: this study evaluates the level of agreement between visual parameters tested using odysight, a mobile application, and standards in office methods.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * able to correctly distinguish the body laterality (left and right) * able to recognize alphabet letters and read french * affiliated to or beneficiary of the french health care system * signed/written informed consent * subject presenting a level of visual acuity of one of his eyes that fits to one of the pre-set cohort (visual acuity between +1.0 and +0.7 logmar, between +0.6 and +0.3 logmar or between +0.2 and 0.0 logmar); the two eyes can be included in two different cohorts. exclusion criteria: * any pathology that is considered by the investigator as capable of affecting the quality of the main evaluation criteria. * pregnant and breastfeeding women. * subject not considered by the investigator or designee to correctly use odysight modules after the training session
peritoneal damage in laparoscopic surgery

Conditions: Peritoneal Damage

Summary: the investigators hypothesized that applying a low intraperitoneal pressure pneumoperitoneum (≤ 8mmhg) during laparoscopic cholecystectomy, the adverse impact on the surgical peritoneal environment (measured as gene expression of extracellular matrix, adhesion and inflammatory cytokine as well as oxidative stress response and apoptotic index), can be minimized and probably clinical outcomes might be better.

cholelithiasis is one of the most frequent abdominal diseases requiring surgical treatment. laparoscopic cholecystectomy is currently the procedure of choice to remove the gallbladder. there is growing evidence that increased intra-abdominal pressure pneumoperitoneum, even for short periods of time, is associated with both transient and sometimes persistent adverse effects that might negatively affect the surgical peritoneal environment .there are some studies that have demonstrated that using low intraperitoneal pressure pneumoperitoneum, undesired effects like adverse impact on peritoneal tissue and negative clinical outcomes could be reduced.therefore intraperitoneal pressure target during laparoscopy should be the lowest to allow surgery be securely performed. many strategies have been tested in order to improve the volume of gas can be insufflated inside the abdominal cavity while maintaining low pneumoperitoneum pressure during laparoscopy.so far the most studied strategy has been deep neuromuscular blockade.however the effect of the depth of neuromuscular blockade in the intraabdominal volume is still controversial as sometimes in humans its benefits are marginal.there is scarce information in the medical literature regarding the adverse impact on peritoneal tissue of high pneumoperitoneum pressure during laparoscopy in humans. in addition available data are provided by non-prospective, non-randomized and small sample studies, so randomized controlled trials are required to ascertain this issues.to our knowledge our study is the first prospective and randomized controlled trial in humans aiming to study the adverse impact of high pressure pneumoperitoneum on peritoneal tissue as well as to associate it with clinical outcomes.

Eligibility criteria:
inclusion criteria: * patients older than 18 years, signed informed consent, undergoing laparoscopic cholecystectomy for symptomatic cholelithiasis or gallbladder polyps. exclusion criteria: * emergency surgery. * previous surgery at supramesocolic compartment. * previous peritoneal inflammatory process. * pregnancy or breastfeeding. * patient refusal to participate in the study

Keywords: low pressure pneumoperitoneum standard pressure pneumoperitoneum laparoscopy cholecystectomy
a study of tln-254 in participants with relapsed or refractory t-cell lymphoma

Conditions: Lymphoma

Summary: the primary purpose of this study is to evaluate the anti-tumor activity of tln-254 monotherapy in participants with relapsed or refractory t-cell lymphoma.


Eligibility criteria:
inclusion criteria: age: 1. at least 18 years of age at the time of signing the informed consent form (icf). type of participant and disease characteristics: 2. cohort 1: peripheral t-cell lymphoma (ptcl) that has relapsed after, or not responded to at least one prior systemic treatment regimen. participants with anaplastic large cell lymphoma (alcl) should have received prior brentuximab vedotin treatment. * nodal t-follicular helper (tfh) cell lymphoma angioimmunoblastic; follicular helper t-cell lymphoma, angioimmunoblastic type (angioimmunoblastic t-cell lymphoma). * nodal tfh cell lymphoma, follicular type; follicular helper t-cell lymphoma, follicular type. * nodal tfh cell lymphoma, not otherwise specified (nos); follicular helper t-cell lymphoma, nos. * ptcl, nos. * anaplastic large-cell lymphoma, alkaline phosphatase (alk) positive. * anaplastic large-cell lymphoma, alk negative. cohort 2: relapsed/refractory ctcl which has relapsed after, or not responded to at least two prior systemic treatments. * sezary syndrome * mycosis fungoides 3. participant must have measurable disease at study entry. 4. freshly biopsied or archival tissue available. diagnostic assessments: 5. eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. 6. adequate organ function. contraception: 7. participants must accept and follow the pregnancy prevention plan. exclusion criteria: medical conditions: 1. participants must not have prior systemic anti-cancer treatment less than or equal to (≤) 5 half-lives or 4 weeks, allogeneic sct≤90 days or autologous sct ≤60 days prior to study intervention initiation. 2. participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study. 3. current or past history of central nervous system (cns) involvement. other exclusions: * pregnant or lactating women. * unable to swallow tablets.

Keywords: relapsed or refractory cutaneous t cell lymphoma relapsed or refractory peripheral t cell lymphoma
long-term safety and efficacy of esk-001 in moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis; Psoriasis (PsO); Psoriasis; Moderate Psoriasis; Severe Psoriasis

Summary: the objective of the esk-001-018 long term extension is to evaluate the safety and efficacy of esk-001 over time. the scientific questions it aims to answer are: * how safe is taking esk-001 long-term in people with moderate to severe plaque psoriasis? * does taking esk-001 long-term reduce the severity of people's plaque psoriasis? patients will enter the long-term extension study following completion of one of the parent studies (esk-001-016 or esk-001-017) and will receive open-label esk-001 twice daily for 24 weeks. after 24 weeks, the first 200 patients meeting at least pasi-75 clinical response will be randomly assigned to receive esk-001 or placebo. at any point during this time, the patients losing the initial clinical response may return to the open-label esk-001 treatment. patients who complete week 48 will return to open-label esk-001 treatment and they will receive esk-001 until the end of the study or discontinuation. all the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label esk-001 for the remainder of the study. patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of esk-001 in moderate to severe plaque psoriasis. patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.


Eligibility criteria:
inclusion criteria: 1. males or females, age ≥18 years 2. completed either of the two previous (parent) studies of esk-001 (esk-001-016 or esk-001-017) 3. esk-001 safety and tolerability were acceptable in the parent study 4. women of childbearing potential (wocbp) and males who are sexually active with wocbp must agree to adhere to highly effective methods of contraception for the entirety of the study exclusion criteria: 1. pregnant, lactating, or planning to get pregnant during the study period 2. any acute or chronic illness/condition or evidence of an unstable clinical condition that in the investigator's judgment will substantially increase the risk to the patient if they continue to receive esk-001 treatment in this extension study 3. deemed by the investigator to be inappropriate for the study or unable to comply with the protocol

Keywords: psoriasis pasi safety esk-001